Publication: Drugs in a brave new world of trips+ schemes : the case for legal ceilings on extra patent protection
Loading...
Identifiers
Publication date
2013-03
Defense date
Authors
Advisors
Tutors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Carlos III de Madrid
Impact
Export
Abstract
El comercio de medicamentos genéricos es una condición previa para que los pacientes
y autoridades públicas en los países en desarrollo adquieran medicinas asequibles en los mercados
farmacéuticos. Sin embargo, la incansable promoción de estándares de protección de patentes por los
países exportadores de tecnología está minando la posibilidad la producción y distribución sostenible
de genéricos a escala global. En gran medida, los países desarrollados actúan como apoderados de las
estrategias de captación de rentas de las empresas farmacéuticas. Las coaliciones de interés público sólo
pueden vencer esta desigual batalla (en múltiples frentes paralelos) promoviendo una nueva Declaración
sobre el ADPIC como techo legal para la protección de patentes farmacéuticas en el mundo en desarrollo,
complementando así la histórica Declaración de Doha de 2001 sobre el ADPIC y la salud pública. Alternativamente,
varias instituciones globales con competencias concurrentes en este área están disponibles
para promover una solución legal similar.
Trade in generics is a prerequisite for patients as well as public health authorities in the developing world in order to purchase affordable medicines in pharmaceutical markets. However, the relentless promotion of stringent global patent protection standards by technology exporting countries is undermining the ability of sustainable generic production and distribution on a global scale. To a great extent, developed countries are acting as proxies of the socially wasteful rent-seeking strategies of pharmaceutical companies. Public interest coalitions can only win the ongoing battle (on multiple parallel fronts) by promoting a new Declaration on TRIPs rules as a legal ceiling for pharmaceutical patent protection in the developing world, to complement the historic 2001 WTO Doha Declaration on TRIPs and public health. Alternatively, several global institutions with concurring competences in this area are already available to promote a similar legal solution.
Trade in generics is a prerequisite for patients as well as public health authorities in the developing world in order to purchase affordable medicines in pharmaceutical markets. However, the relentless promotion of stringent global patent protection standards by technology exporting countries is undermining the ability of sustainable generic production and distribution on a global scale. To a great extent, developed countries are acting as proxies of the socially wasteful rent-seeking strategies of pharmaceutical companies. Public interest coalitions can only win the ongoing battle (on multiple parallel fronts) by promoting a new Declaration on TRIPs rules as a legal ceiling for pharmaceutical patent protection in the developing world, to complement the historic 2001 WTO Doha Declaration on TRIPs and public health. Alternatively, several global institutions with concurring competences in this area are already available to promote a similar legal solution.
Description
Keywords
World trade, Pharmaceutical patents, Flexibilities, Legal ceilings, Access to medicines, Generics, Comercio global, Patentes farmaceúticas, Techos legales, Flexibilidades, Acceso a medicamentos, Genéricos
Bibliographic citation
Cuadernos de derecho transnacional, vol. 5, n. 1, marzo 2013, pp. 229-238